DRUGS IN R&D
Scope & Guideline
Catalyzing discoveries in drug research and development.
Introduction
Aims and Scopes
- Clinical Pharmacology and Drug Development:
The journal emphasizes the study of pharmacokinetics and pharmacodynamics, exploring how drugs behave in the body and their effects on biological systems. This includes research on drug interactions, bioavailability, and the impact of various factors on drug metabolism. - Therapeutic Innovation and Efficacy:
It highlights innovative therapies, including novel drugs and repurposed medications, focusing on their therapeutic efficacy in treating various conditions. The journal covers a wide range of diseases, from oncology to infectious diseases, showcasing advances in treatment options. - Patient-Centric Research:
The importance of patient-reported outcomes and real-world evidence is underscored, reflecting a commitment to incorporating patient perspectives into drug development and clinical practice. - Biosimilars and Drug Comparisons:
A significant area of focus is the evaluation of biosimilars and their comparability to reference products, including studies on safety, efficacy, and pharmacological properties. - Regulatory and Safety Assessments:
The journal contributes to discussions on regulatory challenges and safety assessments in drug development, aiming to inform better practices in clinical trials and post-marketing surveillance.
Trending and Emerging
- Precision Medicine and Pharmacogenomics:
Recent papers highlight the role of pharmacogenomics in tailoring drug therapies to individual genetic profiles, indicating a growing interest in precision medicine approaches that enhance treatment efficacy and minimize adverse effects. - Real-World Evidence and Outcomes Research:
There is an increasing focus on real-world evidence, utilizing data from clinical practice to assess drug effectiveness and safety post-approval. This trend underscores the importance of understanding how treatments perform outside controlled clinical trial settings. - Biosimilars and Comparative Effectiveness:
With the rise of biosimilars, there is a noticeable trend towards comparative studies that evaluate their efficacy and safety against reference biologics, reflecting the market's shift towards cost-effective alternatives. - Drug-Drug Interaction Studies:
Research exploring complex drug-drug interactions, especially in vulnerable populations with comorbidities, is becoming more prevalent, highlighting the need for comprehensive safety profiles in polypharmacy scenarios. - Innovative Drug Delivery Systems:
Emerging studies are focusing on novel drug delivery mechanisms that enhance bioavailability and therapeutic outcomes, such as prolonged-release formulations and nanotechnology applications.
Declining or Waning
- Traditional Pharmacotherapy Studies:
Research focusing solely on traditional pharmacotherapeutic approaches has seen a decrease, as there is a growing emphasis on personalized medicine and targeted therapies that consider individual patient variability. - Basic Laboratory Research:
Studies that primarily focus on preclinical laboratory findings without a direct translational aspect to clinical applications appear to be waning, indicating a trend towards more clinically relevant research. - General Drug Safety Reports:
There is a noticeable decline in the publication of broad safety reports that do not delve into specific drug interactions or patient populations, suggesting a shift towards more targeted safety assessments.
Similar Journals
CLINICAL PHARMACOKINETICS
Exploring Clinical Insights in PharmacokineticsCLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.
ANTI-CANCER DRUGS
Exploring New Horizons in Anti-Cancer TreatmentsANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.
DRUG METABOLISM REVIEWS
Advancing knowledge in pharmacology and toxicology.Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.
ADMET and DMPK
Pioneering research at the intersection of absorption and metabolism.ADMET and DMPK is a premier open-access journal published by IAPC PUBLISHING since 2013, focusing on the rapidly evolving fields of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK (Drug Metabolism and Pharmacokinetics). Catering to researchers, professionals, and students in the realms of pharmacology, toxicology, and medicinal chemistry, this journal plays a crucial role in fostering innovation and collaboration within the interdisciplinary landscape of drug development. With an impressive Q1 ranking in Pharmacology, Toxicology and Pharmaceutics and ranking in the top percentiles across various categories such as Chemistry and Health, ADMET and DMPK provides a reputable platform for high-quality publications. Its global reach, complemented by its open-access model, ensures that valuable research is accessible to a wide audience. As we converge towards 2024, this journal remains dedicated to advancing knowledge and practices that shape the future of drug discovery and safety, making it an essential resource in the scientific community.
DRUGS
Shaping the Future of Pharmaceutical ScienceDRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.
INDIAN JOURNAL OF PHARMACOLOGY
Transforming clinical practices with groundbreaking pharmacological research.INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.
PHARMACEUTICAL RESEARCH
Driving discoveries that shape the future of medicine.PHARMACEUTICAL RESEARCH, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the ever-evolving field of pharmaceutical sciences. With an ISSN of 0724-8741 and an E-ISSN of 1573-904X, this journal has established itself as a critical hub for disseminating innovative research from 1984 to 2024. The journal holds impressive rankings in prominent categories, including Q2 in Biotechnology and Q2 in Pharmaceutical Science, reflecting its robust impact on the global scientific community. The journal aims to provide researchers, professionals, and students with high-quality articles that contribute significantly to the advancement of drug development and medicinal applications. Although it does not currently offer Open Access options, its rigorous peer-review process ensures that only the highest caliber research is published, making it a valuable resource for those seeking to stay at the forefront of pharmaceutical innovation.
Clinical Pharmacology-Advances and Applications
Empowering Research for Better Patient OutcomesClinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.
Clinical Pharmacology in Drug Development
Innovating therapeutics through rigorous research.Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.
Therapeutic Innovation & Regulatory Science
Empowering Researchers Through Open Access DiscoveriesTherapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.